Sharon Townson's most recent trade in Monte Rosa Therapeutics Inc was a trade of 6,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2026 | 6,000 | 197,290 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.14 per share. | 06 Jul 2026 | 6,000 | 73,845 | - | 6.1 | 36,840 | Common Stock |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.25 per share. | 06 Jul 2026 | 5,600 | 68,245 | - | 23.2 | 130,197 | Common Stock |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.13 per share. | 06 Jul 2026 | 400 | 67,845 | - | 24.1 | 9,652 | Common Stock |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.14 per share. | 23 Jun 2026 | 3,000 | 70,845 | - | 6.1 | 18,420 | Common Stock |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2026 | 3,000 | 203,290 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 23 Jun 2026 | 3,000 | 67,845 | - | 20 | 60,000 | Common Stock |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.00 per share. | 17 Jun 2026 | 3,000 | 67,845 | - | 19 | 57,000 | Common Stock |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2026 | 3,000 | 206,290 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.14 per share. | 17 Jun 2026 | 3,000 | 70,845 | - | 6.1 | 18,420 | Common Stock |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2026 | 6,000 | 209,290 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.87 per share. | 29 May 2026 | 6,000 | 67,845 | - | 19.9 | 119,220 | Common Stock |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.14 per share. | 29 May 2026 | 6,000 | 73,845 | - | 6.1 | 36,840 | Common Stock |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 158,000 | 158,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 35,000 | 71,000 | - | - | Common Stock | |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 15.17 per share. | 02 Jan 2026 | 3,155 | 67,845 | - | 15.2 | 47,861 | Common Stock |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 161,000 | 161,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 36,000 | 36,000 | - | - | Common Stock | |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 78,550 | 78,550 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) |